Liraglutide suppresses protein kinase B (Akt) phosphorylation in pancreatic cancer cells by activating GLP-1R, thus inhibiting tumor growth via suppression of the PI3K/Akt signaling pathway [63]. Here, AKT1 is linked to familial pancreatic carcinoma.